Agios Recruits Rare Disease Leader Brian Goff As CEO To Execute Commercial Transition
Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.
You may also be interested in...
Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.